Stock Evaluator: TransMedics Group, Inc. (TMDX)

TransMedics Group, Inc. TMDX

$92.21 0.83 0.91%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 564,167
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics TMDX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,202.8 $380.3 61%
Shares Out (Mil) 40.8 41.2 43%
Institutional Ownership 97.1% 84.0% 72%
Float (Mil) 33.6 35.2 38%
Beta 2.10 0.85 93%
Avg Daily Volume (000s) 1,589 341 76%
Price Change
(52-week)
(20.2%) 59.6% 35%
Growth TMDX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 88.3% 11.8% 98%
Net Income (5yr) 53.9% (5.6%) 95%
EPS (5yr) 44.0% 10.6% 91
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 90.0% (16.0%) 98%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 9 10 10
Current EPS $0.451 $1.670 $2.486
Month Ago EPS $0.499 $1.513 $2.254
# Rev Up 0 1 0
# Rev Down 2 1 1
Three Months Ago EPS $0.530 $1.559 $2.306
Year/Year Chg (2.6%) (65.7%) (29.4%)
Financials TMDX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $728 $127 45%
Net Income (TTM) (Mil) $145 ($9) 64%
EPS (TTM) $4.191 ($0.300) 83%
Operating Cash Flow (TTM) (Mil) $112 ($1) 52%
Net Cash Flow (TTM) (Mil) $45 $2 69%
Long-Term Debt (Q1) (Mil) $808 $25 63%
Enterprise Value (Q1) (Mil) $3,533 $400 57%
Valuation TMDX Industry
Median
Percentile
(All Stocks)
P/B 5.81 2.62 84%
P/E 23.8 26.0 62%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.5 1.3 28%
Ratios TMDX Industry
Median
Percentile
(All Stocks)
Gross Margin 58.6% 59.1% 71%
Net Margin 19.9% (4.5%) 78%
ROA 11.7% (11.0%) 89%
ROE 31.9% (8.5%) 88%
Liabilities to Assets 63.7% 45.9% 59%
F-Score 3 4 18%

TransMedics Group, Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors